Inferring optimal MTAP homozygous loss (homozygous deletion) detection in urothelial cancer: Prevalence and co-alterations based upon treatment exposure and anatomical location.
Abhishek Tripathi(City of Hope), R. Graf(Foundation Medicine (United States)), Eliane Cortez(Lund University), Gerald Li(Foundation Medicine (United States)), Sumanta Kumar Pal(City Of Hope National Medical Center), Adanma Ayanambakkam(University of Oklahoma Health Sciences Center), Karine Tawagi(University of Illinois Chicago), Jeffrey S. Ross(Foundation Medicine (United States)), Natalie Danziger(Foundation Medicine (United States)), Neel Belani, Benjamin A. Gartrell
Cited by 0
Related Papers
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
|JAMA Oncology|2021|185
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
|The Journal of Experimental Medicine|2013|137
Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
|The Journal of Urology|2023|65
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
|JNCI Cancer Spectrum|2022|11